Feb 24, 2021
Viracta Therapeutics Announces Closing of Merger with Sunesis Pharmaceuticals and $65M Private Placement
Feb 16, 2021
Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma
Feb 11, 2021
Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences
Dec 07, 2020
Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA
Nov 30, 2020
SHAREHOLDER ALERT: WeissLaw LLP Investigates Sunesis Pharmaceuticals, Inc.
Feb 04, 2020
Viracta Therapeutics to Present at the 2020 BIO CEO & Investor Conference
Dec 08, 2019
Viracta Announces Positive Phase 1b/2 Data Presented at Oral Presentation on Lead Program for Epstein-Barr Virus (EBV)-associated Relapsed/Refractory Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
Nov 06, 2019
Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting
Oct 28, 2019
Viracta Therapeutics Announces Closing of Series D Preferred Stock Financing
Jun 03, 2019
Viracta Presents New Clinical Results on Lead Epigenetic Drug Candidate for EBV-Associated Lymphomas at the 2019 ASCO Annual Meeting
May 15, 2019
Viracta to Present New Clinical Results on Lead Epigenetic Drug Candidate Nanatinostat at the 2019 ASCO Annual Meeting
Apr 16, 2019
Viracta Receives Orphan Drug Designation from the US FDA for its Lead Epigenetic Drug Candidate Nanatinostat for EBV-Associated Cancers